Total Payments
$7,056
2024 Payments
$5,148
Companies
10
Transactions
15
Medicare Patients
7,277
Medicare Billing
$4.6M
Payment Breakdown by Category
Consulting$6,012 (85.2%)
Food & Beverage$1,044 (14.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $6,012 | 4 | 85.2% |
| Food and Beverage | $1,044 | 11 | 14.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $2,560 | 4 | $0 (2024) |
| Astellas Pharma Global Development | $1,857 | 2 | $0 (2024) |
| EMD Serono, Inc. | $1,762 | 1 | $0 (2024) |
| GENZYME CORPORATION | $207.35 | 1 | $0 (2018) |
| Merck Sharp & Dohme LLC | $149.50 | 1 | $0 (2023) |
| PFIZER INC. | $138.18 | 2 | $0 (2024) |
| Foundation Medicine, Inc. | $130.25 | 1 | $0 (2018) |
| Bayer HealthCare Pharmaceuticals Inc. | $125.00 | 1 | $0 (2019) |
| Aveo Pharmaceuticals, Inc. | $100.54 | 1 | $0 (2024) |
| Eisai Inc. | $26.13 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,148 | 9 | Astellas Pharma Global Development ($1,857) |
| 2023 | $1,444 | 3 | Eli Lilly and Company ($1,295) |
| 2019 | $125.00 | 1 | Bayer HealthCare Pharmaceuticals Inc. ($125.00) |
| 2018 | $337.60 | 2 | GENZYME CORPORATION ($207.35) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,762.00 | General |
| 11/21/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $100.54 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| 09/15/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $14.88 | General |
| 06/03/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 06/02/2024 | Eisai Inc. | — | Food and Beverage | In-kind items and services | $26.13 | General |
| 05/31/2024 | Astellas Pharma Global Development | Padcev (Drug) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: Oncology | ||||||
| 05/31/2024 | Astellas Pharma Global Development | Padcev (Drug) | Food and Beverage | In-kind items and services | $106.74 | General |
| Category: Oncology | ||||||
| 05/09/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $3.18 | General |
| Category: ONCOLOGY | ||||||
| 12/14/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| 11/29/2023 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $44.98 | General |
| 02/17/2023 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Food and Beverage | In-kind items and services | $149.50 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2019 | Bayer HealthCare Pharmaceuticals Inc. | Xofigo (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 10/26/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Food and Beverage | In-kind items and services | $207.35 | General |
| 05/31/2018 | Foundation Medicine, Inc. | FOUNDATIONACT (Device), FOUNDATIONFOCUS, FOUNDATIONONE CDX | Food and Beverage | Cash or cash equivalent | $130.25 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 43 | 1,809 | 87,226 | $4.5M | $1.2M |
| 2022 | 50 | 1,832 | 78,938 | $4.3M | $1.2M |
| 2021 | 46 | 1,922 | 89,073 | $4.1M | $1.1M |
| 2020 | 48 | 1,714 | 80,302 | $4.0M | $1.1M |
Total Patients
7,277
Total Services
335,539
Medicare Billing
$4.6M
Procedure Codes
187
All Medicare Procedures & Services
187 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 32 | 12,200 | $1.4M | $524,583 | 36.7% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 24 | 17,135 | $1.1M | $403,605 | 36.7% |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | Office | 2023 | 19 | 9,113 | $309,842 | $89,299 | 28.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 223 | 416 | $246,098 | $41,774 | 17.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 113 | 345 | $81,420 | $33,558 | 41.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 12 | 1,500 | $83,040 | $27,542 | 33.2% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 11 | 168 | $194,040 | $13,029 | 6.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 16 | 84 | $336,420 | $11,078 | 3.3% |
| J1442 | Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | Office | 2023 | 15 | 11,280 | $22,560 | $8,703 | 38.6% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 35 | 66 | $60,594 | $8,042 | 13.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 74 | 126 | $34,902 | $6,260 | 17.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 108 | 243 | $49,329 | $5,412 | 11.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 126 | 384 | $54,720 | $4,619 | 8.4% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 27 | 29 | $24,476 | $4,012 | 16.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 28 | 28 | $10,976 | $3,691 | 33.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 38 | 49 | $11,025 | $2,285 | 20.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 66 | 232 | $7,656 | $1,949 | 25.5% |
| J0640 | Injection, leucovorin calcium, per 50 mg | Office | 2023 | 28 | 581 | $12,782 | $1,805 | 14.1% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 45 | 12,750 | $63,750 | $1,585 | 2.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 31 | 71 | $13,490 | $1,575 | 11.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 13 | $5,811 | $1,299 | 22.4% |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | Office | 2023 | 29 | 421 | $36,206 | $1,202 | 3.3% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 66 | 1,190 | $72,590 | $988.22 | 1.4% |
| J9190 | Injection, fluorouracil, 500 mg | Office | 2023 | 32 | 551 | $15,979 | $984.22 | 6.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 63 | 87 | $6,003 | $959.76 | 16.0% |
About Dr. Melissa Reimers, MD
Dr. Melissa Reimers, MD is a Internal Medicine healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/06/2013. The National Provider Identifier (NPI) number assigned to this provider is 1578908414.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Melissa Reimers, MD has received a total of $7,056 in payments from pharmaceutical and medical device companies, with $5,148 received in 2024. These payments were reported across 15 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($6,012).
As a Medicare-enrolled provider, Reimers has provided services to 7,277 Medicare beneficiaries, totaling 335,539 services with total Medicare billing of $4.6M. Data is available for 4 years (2020–2023), covering 187 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location Saint Louis, MO
- Active Since 05/06/2013
- Last Updated 04/17/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1578908414
Products in Payments
- Padcev (Drug) $1,857
- NO PRODUCT DISCUSSED (Drug) $207.35
- WELIREG (Drug) $149.50
- PADCEV (Biological) $135.00
- FOUNDATIONACT (Device) $130.25
- Xofigo (Drug) $125.00
- FOTIVDA (Drug) $100.54
- INLYTA (Drug) $3.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Saint Louis
Dr. John Lasala, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Dr. Mark Fesler, Md, MD
Internal Medicine — Payments: $700,896
Internal Medicine $700,896
Dr. Katie Schroeder, Md, MD
Internal Medicine — Payments: $659,683
Internal Medicine $659,683
Edward Charbek, Md, MD
Internal Medicine — Payments: $260,967
Internal Medicine $260,967
Dr. Michael Reschak, M.d, M.D
Internal Medicine — Payments: $245,910
Internal Medicine $245,910
Dr. Osler Jay Guzon, Md, MD
Internal Medicine — Payments: $237,841
Internal Medicine $237,841